Proteolix, Inc. to be Acquired By Onyx Pharm...(oping and marketing Nexavar® a smal...),Health

Date:10/12/2009

oping and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

About Proteolix, Inc.

Founded in December 2003, Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of highly specific proteasome inhibitors, and is currently in multiple Phase 2 clinical studies to evaluate its safety and efficacy in multiple myeloma and other malignancies. Proteolix is also developing a pipeline of novel proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor.

Venture capital investors in Proteolix include U.S. Venture Partners, Advanced Technology Ventures, Latterell Venture Partners, Delphi Ventures, The Vertical Group, Nomura Phase4 Ventures and Westfield Capital Management.

    CONTACT:

    Investors:
    Craig C. Parker
    Senior VP, Finance and Corporate Development
    & Chief Financial Officer
    650-266-2610
    investors@proteolix.com

    Media Inquiries:
    BCC Partners
    Karen L. Bergman or Michelle Corral
    650-575-1509 or 415-794-8662

(i) National Cancer Institute, Surveillance Epidemiology and End Results, 2007 Facts and Figures

(ii) International Agency for Research on Cancer, GLOBOCAN 2002 database

SOURCE Proteolix, Inc.

'/>"/>

SOURCE Proteolix, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Reportlinker Adds Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C. diff and other Hospital Acquired Infections) Report
2. To: All Persons and Entities Who Purchased or Acquired Bristol-Myers Common Stock Between the Close of the Market on March 21, 2006, Through August 8, 2006, Inclusive
3. Avacor(R), Premier Provider of Hair Growth Solutions, Acquired By Investor Group.
4. Blue Cross Blue Shield of Michigan-owned DenteMax Acquired by Dental Network of America
5. Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization
6. Despite Generic Erosion of Key Brands, the Hospital-Acquired Gram Negative Infections Drug Market Will Increase by $1 Billion from 2008 to 2018
7. MedServe to be Acquired by Stericycle for $185 Million
8. Brockton Mayor, James E. Harrington Calls Press Conference to Unveil Newly Adopted Auto Emissions Technology Acquired With Federal Stimulus Money
9. Versailles Group Announces Accentus, Inc. Acquired by High Road Capital Partners
10. All Persons Who Purchased or Acquired the Common Stock of Sunrise Senior Living, Inc. (Sunrise) Between February 26, 2004 and July 28, 2006, Inclusive, and Were Damaged Thereby (The Class)
11. Scent To Sleep All Natural Non-Drowsy Sleep Mist Acquired by Innovative Custom Products, Inc. (ICP)